Current report
Open the filing on sec.gov
Kairos Pharma, Ltd. (KAPA)
NYSE: KAPA · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2023
The companyfiscal 2025, as filed
Revenuen/a
Net income-$5.4M-109.3%
Earnings per share$-0.30-30.4%
Operating cash flow-$3.4M+13.0%
Cash$4.5M+253.1%
Debtn/a
Shareholders’ equity$6.3M+32.8%
Shares, diluted18.4M+62.3%
Return on equity-85.9%
The recordfrom its filings
Filings in 202625
Newest filingNov 5 · 8-K
Annual reportMar 31, 2026
Quarterly reportAug 12, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$5.8MCash from operations -$4.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.